Join Nuventra at this year’s annual American Association of Pharmaceutical Scientists (AAPS) meeting, PharmSci 360. The meeting will be held in person and virtually from October 17 – 20. Request a complimentary 30-minute consultation with one of our former FDA Reviewers or connect with us via the Connect360 networking platform or through our virtual booth.
Nuventra’s team of experienced consultants includes several former FDA Reviewers who will be available to meet during PharmSci 360 for complimentary 30-minute consultations. They can answer questions, offer advice on your regulatory strategy, interpret guidances, or offer their opinions on various clinical pharmacology issues.
Meet the Former FDA Reviewers
Suliman Al-Fayoumi, MBA, Ph.D. has over 23 years of experience in regulatory science and the pharmaceutical industry including experience in clinical pharmacology, biopharmaceutics, pharmacology, toxicology and translational sciences. In addition, Dr. Al-Fayoumi spent 8 years as a Senior Clinical Pharmacology and Biopharmaceutics Reviewer at FDA, 4.5 years at Novartis Pharma, and 8 years at two small biotech companies.
Iftekhar Mahmood, Ph.D. has more than 25 years of clinical pharmacology experience at the FDA. Dr. Mahmood worked in both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). During this period, Dr. Mahmood worked on neurological products, therapeutic proteins, coagulation factors, and immunoglobulins.
Gene Williams, Ph.D. has over 25 years of experience in clinical pharmacology, 20 of which occurred at the FDA, first as an FDA Primary Reviewer and subsequently as an FDA Team Leader. He has worked on more than 400 different drugs as an FDA Primary Reviewer and 600 as an FDA Team Leader. The majority of his time at the FDA was spent reviewing oncology applications.
AAPS PharmSci 360
AAPS PharmSci 360 combines the energy of a large scientific conference with the intimacy of a small niche gathering. The meeting features six tracks, five of which are split equally between chemical and biomolecule drug programming. These tracks encompass many areas making the biggest headlines today. You can focus on one track for a “small meeting” experience, or move across tracks to get a multi-discipline perspective.
Learn more about AAPS here.